KOSDAQBiotech & Pharma065660

Anterogen

₩15,110▲ 0.27%2026-10-02 close

Market Cap

₩150.5B

Turnover

₩100M

Volume

9,636 shares

Shares out.

10M

PER

—

PBR

1.9×

EPS

-₩162

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Allostem's Japan Entry, Losses Still in Progress

Anterogen has cleared its first global gateway with Allostem's Japan regenerative-medicine product approval and a new US clinical entry, even as consolidated operating losses continue.

1
Allostem received regenerative-medicine product approval from Japan's health ministry, marking the first overseas stem-cell therapy approval for a Korean drug developer.
2
In the US, an FDA IND for the DEB indication was approved, and Phase 2 trials are being prepared at Stanford and University of Miami hospitals.
3
Annual revenue has grown modestly since 2022, and the operating loss ratio to sales improved from -78.1% in 2023 to -32.3% in 2025.
4
The consolidated operating loss more than doubled in Q1 2026 versus the prior quarter before narrowing again in Q2, showing significant quarter-to-quarter volatility.
5
The company currently pays no dividend, and the stock trades at a premium to its net asset value per share.

Business structure

Anterogen is a stem-cell therapeutics company founded in 2000 that develops multiple pipeline candidates based on two proprietary platforms: TED, a standardized embryonic stem cell differentiation technology, and FECS, a three-dimensional functional spheroid technology.

In 2012 the company commercialized Cupistem, the world's first adipose-derived stem cell therapy to receive marketing approval, for Crohn's disease fistula, and it remains a core revenue driver today.

The company also distributes Remodulin, an orphan drug for pulmonary arterial hypertension, which supplements its stable revenue base.

Allostem, a treatment for dystrophic epidermolysis bullosa (DEB) that was licensed to Japan-Taiwan partner Ishin Pharma in 2015, received formal regenerative-medicine product approval in Japan in 2026, becoming a symbolic case of the company's global expansion.

Beyond these, five pipeline candidates for Parkinson's disease, spinal cord injury, critical limb ischemia, periorbital wrinkle improvement, and an acne-scar treatment (CureSkin) are in clinical stages, while a herpes zoster candidate, ANT-501, has passed a non-clinical toxicity study.

Domestically, competitors including Kolon Life Sciences, Medipost, Cha Bio, Nature Cell, Kangstem Biotech, CoreStem Chemon, and Pharmicell are developing stem-cell and cell-therapy products for different indications, so competition tends to be indication-specific rather than head-to-head.

Globally, in the DEB space, Krystal Biotech's gene therapy Vyjuvek has already been approved in the US and Japan, making it a key benchmark for how well Allostem can establish itself overseas.

The company is diversifying its business structure across three pillars: cell-therapy product sales (Cupistem, Remodulin), licensing income, and future overseas revenue growth from Allostem.

Earnings trend

Quarterly revenue · Operating profit

₩1.9B-₩500M25Q2₩2B-₩400M25Q3₩2B-₩500M25Q4₩2.1B-₩1.1B26Q1₩2.2B-₩500M26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩6.6B-₩4.6B2022₩6.5B-₩5.1B2023₩6.9B-₩3.7B2024₩7.5B-₩2.4B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩1.9B	-₩500M	−24.1%
2025Q3	₩2B	-₩400M	−19.9%
2025Q4	₩2B	-₩500M	−23.7%
2026Q1	₩2.1B	-₩1.1B	−51.8%
2026Q2	₩2.2B	-₩500M	−21.7%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩6.6B	-₩4.6B	-₩6.8B	−70.5%	−6.4%	16.2%
2023	₩6.5B	-₩5.1B	-₩2.8B	−78.1%	−2.2%	15.4%
2024	₩6.9B	-₩3.7B	-₩2.3B	−54.1%	−2.1%	5.3%
2025	₩7.5B	-₩2.4B	-₩1.4B	−32.3%	−1.6%	0.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23

Earnings analysis

Consolidated revenue slipped slightly from KRW 6.59 billion in 2022 to KRW 6.50 billion in 2023, then grew again to KRW 6.93 billion in 2024 and KRW 7.54 billion in 2025, showing a gradual upward trend.

The operating loss widened from KRW -4.65 billion in 2022 to KRW -5.07 billion in 2023, but then narrowed markedly to KRW -3.75 billion in 2024 and KRW -2.43 billion in 2025, with the operating loss ratio to sales improving from -78.1% in 2023 to -32.3% in 2025.

Net loss attributable to owners also shrank steadily from a large KRW -6.84 billion in 2022 to KRW -2.84 billion in 2023, KRW -2.29 billion in 2024, and KRW -1.37 billion in 2025.

On a quarterly basis, the operating loss stayed relatively stable from Q2 2025 (KRW -0.45 billion) through Q3 2025 (KRW -0.41 billion), but net loss jumped to KRW -0.51 billion in Q4 2025, and the operating loss widened further to KRW -1.10 billion with a net loss of KRW -0.88 billion in Q1 2026, before both narrowed again to KRW -0.48 billion and KRW -0.15 billion, respectively, in Q2 2026, illustrating meaningful quarter-to-quarter volatility.

On a standalone basis, Q1 2026 revenue reportedly rose 32.4% year over year on higher Remodulin and Cupistem sales with improved gross profit, yet the consolidated loss widened by a much larger margin over the same period, suggesting that consolidation-level items such as R&D spending may have weighed on the group figure.

Over the most recent four quarters (Q3 2025 through Q2 2026), the combined net loss attributable to owners totaled roughly KRW -1.62 billion, a scale not dramatically different from the preceding four-quarter period.

Operating cash flow has remained negative every year, though the outflow narrowed from KRW -1.98 billion in 2022 and KRW -1.99 billion in 2023 to KRW -0.86 billion in 2024 and KRW -1.02 billion in 2025.

The debt ratio declined from 16.2% in 2022 to just 0.9% in 2025, indicating limited leverage pressure from a balance-sheet standpoint.

Industry analysis

Global market research firm MarketsAndMarkets forecasts that the stem-cell therapy market will grow from roughly $480 million currently to about $3.65 billion by 2035, a compound annual growth rate of 25.3%.

By region, North America holds the largest share, while Europe is growing fastest at a 48.3% compound annual rate. In Korea, an amendment to laws governing advanced regenerative medicine and advanced biopharmaceuticals that took effect in February 2025 is expected to expand access to regenerative treatments.

However, Korean regulators are known to apply strict standards, including clinical significance criteria, leaving uncertainty around the pace of domestic commercialization for stem-cell therapies.

Within the competitive landscape, companies tend to focus on different indications, and Anterogen stands out this year as the first Korean company to obtain a stem-cell therapy approval in Japan, positioning it relatively ahead in terms of overseas expansion.

On the global stage, however, Krystal Biotech's gene therapy Vyjuvek, already approved in the US and Japan, has established itself as the benchmark treatment in the DEB market, meaning Allostem enters as a later mover.

Several domestic peers have previously experienced friction with regulators or outright rejection of marketing applications during clinical review, underscoring that regulatory risk remains a persistent feature across the industry.

Outlook

The most visible near-term catalyst is Allostem's foothold in the Japanese market.

The company shipped its first export batch of 1,400 sheets (worth roughly KRW 2.5 billion at the insured price) to Japan in July 2026, and the pace of future cold-chain supply-chain buildout and additional supply contracts will determine how quickly this translates into revenue.

In the US, an FDA IND for the DEB indication has been approved, with Phase 2 trials being prepared at Stanford and University of Miami hospitals, giving the company a relatively rare multi-country development structure among Korean drug developers.

A diabetic foot ulcer treatment (believed to be ALLO-ASC-SHEET) has reportedly received FDA RMAT designation and its associated expedited-review benefits, though a Phase 2 US trial failure for the program was reported in February 2025, making the outcome of this renewed effort a point of attention.

The remaining clinical pipeline—covering Parkinson's disease, spinal cord injury, critical limb ischemia, periorbital wrinkle improvement, and the acne-scar treatment CureSkin—is at various stages, with no specific data-readout timelines yet disclosed.

The herpes zoster candidate ANT-501 has cleared a non-clinical toxicity study and is positioning for the next stage toward clinical entry.

Management has stated it plans to use the Japan approval of Allostem as a springboard to pursue the US market, making progress on the US Phase 2 trial a key variable in the company's global expansion story going forward.

Valuation

PER

—

PBR

1.9×

ROE

-1.9%

EPS

-₩162

BPS

₩8,076

Dividend per share

₩0

Anterogen remains in an operating-loss phase, making earnings-based valuation metrics such as PER difficult to apply, so the market tends to assess the stock mainly through the price-to-book (PBR) lens.

The current share price trades above net asset value per share, reflecting a degree of premium relative to book value.

The company currently pays no dividend, limiting the investment appeal from a yield perspective, which is consistent with the general profile of early-stage growth biotech firms that have yet to achieve stable profitability.

While the multi-year trend of improving operating loss ratios is worth noting, quarterly loss figures have fluctuated considerably, making it difficult to draw firm valuation conclusions from any short window of results.

Ultimately, the pace of Allostem's overseas revenue expansion and progress in the US clinical program stand out as the key variables that could serve as grounds for any future market re-rating.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23

Bull factors

A Tangible First Step in Overseas Expansion

Allostem received regenerative-medicine product approval from Japan's health ministry and actually exported its first commercial batch in July 2026, making Anterogen the first Korean drug developer to both secure an overseas stem-cell therapy approval and realize revenue from it.

In the US, an FDA IND for the DEB indication has also been approved, with Phase 2 trials being readied at Stanford and University of Miami hospitals, establishing a multi-country development structure.

The Japan approval carries symbolic significance beyond a simple regulatory milestone, as it could serve as a springboard for future US market entry.

A Multi-Year Trend of Improving Loss Ratios

The operating loss ratio to sales improved steadily from -78.1% in 2023 to -32.3% in 2025, and net loss attributable to owners shrank sharply from KRW -6.84 billion in 2022 to KRW -1.37 billion in 2025.

Operating cash outflow also eased from roughly KRW -2 billion in 2022–2023 to about KRW -0.9 to -1.0 billion in 2024–2025. The debt ratio likewise fell from 16.2% in 2022 to just 0.9% in 2025, indicating limited balance-sheet pressure.

A Broad Pipeline with Established Regulatory Status

Beyond commercial revenue from Cupistem and Remodulin, the company simultaneously runs five clinical pipelines covering Parkinson's disease, spinal cord injury, critical limb ischemia, periorbital wrinkle improvement, and the CureSkin acne-scar treatment.

The diabetic foot ulcer program has received FDA RMAT designation with expedited-review benefits, and Allostem itself is reported to have previously secured FDA RMAT and Breakthrough Therapy Designation status.

Early-stage pipeline assets are also advancing sequentially, as seen in the herpes zoster candidate ANT-501 clearing a non-clinical toxicity study.

Bear factors

Persistent Operating Losses and Quarterly Volatility

Even with multi-year improvement in the loss ratio, the company still posted an operating loss of KRW -2.43 billion in 2025, and the timing of any turn to profitability remains uncertain.

In Q1 2026, the operating loss widened to KRW -1.10 billion and the net loss to KRW -0.88 billion, illustrating substantial quarter-to-quarter volatility in results.

The fact that consolidated losses widened sharply during a period of standalone revenue growth suggests the presence of harder-to-predict variables such as subsidiary-level costs.

A Small Revenue Base and Early-Stage Overseas Sales

Annual revenue in 2025 was still relatively small at KRW 7.54 billion, and Allostem's first Japan shipment was worth only about KRW 2.5 billion at the insured price, meaning commercial scale has not yet been proven.

Numerous execution variables remain, including cold-chain supply-chain buildout, additional supply contracts, and expanded insurance listing, so the pace at which this translates into revenue bears watching.

The US clinical program is still at an early stage, and actual commercialization is expected to take several more years.

Pipeline Execution Risk and Product Lifecycle Issues

A Phase 2 US trial failure for the diabetic foot ulcer treatment was reported in February 2025, and despite the subsequent RMAT designation, further setbacks in any renewed attempt cannot be ruled out.

The cell therapy product Quincel reportedly had its marketing authorization removed in June 2026 due to expiration, pointing to ongoing product lifecycle management issues.

Given that regulators both in Korea and abroad tend to apply strict standards such as clinical significance, unexpected delays or rejections remain possible in future pipeline approval reviews.

Risk factors

Regulatory and Approval Risk

Even after Japan's Allostem approval, follow-on administrative steps such as insurance price listing and manufacturing facility inspections remain, and the US program is only at the IND-approval stage, meaning actual marketing approval will still take several more years.

As seen with the earlier US Phase 2 trial failure for the diabetic foot ulcer program, there remains a risk of unexpected outcomes during clinical execution. Regulators both in Korea and abroad continue to apply strict standards, including clinical significance criteria, to cell therapy products.

Capital Depletion and Dilution Risk

Equity attributable to owners declined from KRW 129.44 billion in 2023 to KRW 87.45 billion in 2025, reflecting the erosion of capital by accumulated net losses.

With operating cash flow negative every year, additional funding needed to expand overseas trials, including in the US, could come from external sources such as rights offerings or convertible bonds. This raises the possibility of dilution risk for existing shareholders.

Competitive and Market-Entry Risk

In the DEB treatment market, Krystal Biotech's gene therapy Vyjuvek, already approved in the US and Japan, has established itself as the standard of care, meaning Allostem, as a later entrant, must demonstrate differentiation in price, convenience, or duration of effect.

Domestically, several competitors including Kolon Life Sciences, Medipost, and Nature Cell are also pursuing commercialization of cell therapies in their respective indications, intensifying industry-wide competition for capital and talent.

Establishing a foothold in new markets such as Japan and the US will require time-consuming work to build local distribution and clinician networks.

What to watch next

Mid-November 2026
Q3 2026 results are due to be disclosed, making it worth checking whether revenue growth and the narrowing trend in consolidated operating losses continue, and whether the loss widening seen in Q1 2026 recurs.
Q4 2026
Progress on Allostem's Japan insurance price listing and whether additional supply contracts are signed beyond the initial shipment can be checked to gauge the actual pace of revenue recognition.
H2 2026 through 2027
Whether the first patient dosing begins and enrollment speed in the US Phase 2 trial at Stanford and University of Miami hospitals can be monitored to assess execution on the US development timeline.
From Q4 2026 onward
It will be worth confirming whether additional data readouts or regulatory discussions progress for the remaining clinical pipeline, including the diabetic foot ulcer treatment, CureSkin, and periorbital wrinkle improvement programs.

Overall view

Anterogen has improved its operating loss ratio over multiple years on the back of stable Cupistem and Remodulin sales, and Allostem's 2026 Japan approval and first export represent a relatively uncommon overseas commercialization milestone among Korean stem-cell therapy companies.

At the same time, the company has established a multi-country development structure by preparing a US Phase 2 trial for the DEB indication, and several pipeline assets have secured FDA expedited-development status, confirming regulatory progress.

That said, the company still posts an operating loss every year on a consolidated basis, and quarters such as Q1 2026 have shown significant volatility in results.

With revenue scale still small and overseas sales at an early stage, the actual pace of Allostem's commercial expansion and progress in the US trial remain the key variables for future earnings and financial structure.

The trend of capital erosion, the need for further funding, and competition from already-approved therapies such as Vyjuvek are also factors worth monitoring. This report contains no buy or sell recommendation and is provided for informational purposes only.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.